Abstract:Introduction Currently, there is no specific diagnostic test for immune thrombocytopenia (ITP). MicroRNAs (miRNA) are small, noncoding RNAs involved in the post-transcriptional regulation of gene expression. Aberrant expression of miRNAs has been suggested to have potential diagnostic value. Previous explorative studies have identified several differentially expressed miRNAs in ITP with potential diagnostic value; however, such findings are usually difficult to reproduce. Therefore, we aimed to validate some of these miRNAs in a larger ITP cohort. Methods Based on previous studies in ITP, we selected 12 miRNAs for validation in patients with primary ITP. The following miRNA were selected: miR-199a-5p, miR-33a-5p, miR-195-5p, miR-130a-3p, miR-144-3p, miR-146a-5p, miR-222-3p, miR-374-5p, miR-486-5p, miR-1341-5p, miR-766-3p, miR-409-3p. Blood samples (n=61) were obtained from 2 cohorts of primary ITP and healthy controls. The first cohort included samples from 24 patients with newly diagnosed or persistent ITP from the PROLONG study (NCT00344149); all patients had been treated with corticosteroids +/- IVIG but relapsed or failed to respond. The second cohort included 37 samples obtained from the ITP biobank at Østfold Hospital, Norway; patients had different disease phases and had received different therapies. In addition, 28 samples were obtained from healthy controls. The miRNAs were quantified in citrated plasma using droplet digital PCR (Bio-Rad). Results The mean age of the ITP patients was 51 years (62% female) and of the controls 47 years (64% female). The mean platelet count for all patients was 48.8 ·10 9/L. PROLONG patients had a lower mean platelet count (33 ·10 9/L) than patients from ITP biobank (59 ·10 9/L). Mann-Whitney test showed that miR-199a-5p (p=0.001), miR-33a-5p (p=0.010), miR-374-5p (p=0.009) and miR-146a-5p (p=0.026) were significantly differentially expressed (downregulated) in ITP compared with controls. Subgroup analysis of PROLONG patients showed that 3 additional miRNAs (7 of the 12 miRNAs) were significantly differentially expressed (downregulated) in these ITP patients: miR-130a-3p (p=0.005), miR-766-3p (p=0.010) and miR-409-3p (p=0.001). ROC curve analysis showed good discrimination for miR-199a-5p in all patients with an AUC of 0.718 (95% CI 0.599-0.836), and satisfactory for miR-33a-5p with an AUC of 0.671 (CI 0.549-0.793), 0.673 (CI 0.554-0.792) for miR-374-5p and 0.632 (CI 0.505-0.759) for miR-409-3p (Figure A). Subgroup analysis for each of the two cohorts separately showed higher AUC in PROLONG patients for miR-199a-5p (AUC=0.824; 95% CI 0.708-0.940), miR-374-5p (AUC=0.806; 95% CI 0.688-0.924), and for miR-33a-5p (AUC=0.732; 95% CI 0.597-0.868). The combination of all three miRNAs: miR-199a-5p, miR-33a-5p and miR-374-5p in PROLONG patients resulted in a slight improvement of the AUC to 0.865 (CI 0.767-0.962) (Figure B). Conclusions This study confirms that miR-199a-5p, miR-33a-5p, miR-374-5p and miR-146a-5p are differentially expressed in primary ITP compared with healthy controls. miR-199a-5p shows a good ability to discriminate primary ITP patients from healthy controls. In the PROLONG cohort, both miR-199a-5p and miR-374-5p showed a very good discrimination, probably due to the fact that these patients had early ITP. These findings should be further validated in a prospective cohort of newly diagnosed ITP patients and in patients with other types of thrombocytopenia to explore their potential diagnostic value. Some of these miRNAs have important regulatory functions, particularly in inflammation and apoptosis, so it is essential to evaluate their function and role in the pathogenesis of ITP and their potential use as therapeutic targets.

Plasma long noncoding RNAs lncDC and THRIL as potential diagnostic markers of adult primary immune thrombocytopenia

Aberrant Expression of NLRP3, NLRC4 and NLRP6 Inflammasomes in Patients with Primary Immune Thrombocytopenia

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia

Abnormal Expression of Long Noncoding RNAs in Primary Immune Thrombocytopenia: A Microarray Related Study.

Protecting Minors from Tobacco Products: Public Interest Litigation Enables Enforcement in China

Excessive Expressions of T Cell Activation Markers in Pediatric Immune Thrombocytopenia

Plasma Micrornas Characterising Patients with Immune Thrombocytopenic Purpura.

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

Targeted proteomics profiling reveals valuable biomarkers in the diagnosis of primary immune thrombocytopaenia

Immune Checkpoint-Related Gene Polymorphisms Are Associated with Primary Immune Thrombocytopenia

Megakaryocyte- and Platelet-Derived Microparticles as Novel Diagnostic and Prognostic Biomarkers for Immune Thrombocytopenia

Expression and Prognostic Value of C-reactive Protein in Adult Immune Thrombocytopenia (ITP) Patients.

Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker

Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia

Regulatory Role of Cerna Network in B Lymphocytes of Patients with Immune Thrombocytopenia

Integrating chemokines and machine learning algorithms for diagnosis and bleeding assessment in primary immune thrombocytopenia: A prospective cohort study

The Ifng antisense RNA 1 (IFNG-AS1) and growth arrest-specific transcript 5 (GAS5) are novel diagnostic and prognostic markers involved in childhood ITP

[Expression of Interleukin-18 and Interleukin-18 Receptor Alpha Chain of the Peripheral White Blood Cells in Immune Thrombocytopenia].

Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis

Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia

Increased TRAIL Expression in Peripheral Blood Mononuclear Cells from Patients with Primary Immune Thrombocytopenia and Its Clinical Significance